Amazed by their blind confidence. Just cause they said data should be here by end of Qtr does not mean it won't come sooner. Think it was an 8 week interval check. THLD had some good news recently and are now taking the same drug into phase III trial for pancreatic cancer, a more risky gamble. I like Ziop chances since the drug is a proven winner and is much better with side effects.
Maybe more of the short is wt. covered than we think. They did a big raise a few years back and there are a lot of wts out there. I guess time will tell. Hopefully we get good STS data and some early hints on efficacy in SCLC. That would make Pali a valuable property.
Synthetics remain a black box. Lots of hints on Clinicaltrials .gov.